ClinicalTrials.gg
RecruitingNCT06556446DO-IT CohortUpdated Aug 16, 2024

Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants

An observational study in Ischemic Stroke, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 33 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Insel Gruppe AG, University Hospital Bern · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,800
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern — 7 open to participants now, 7 under way, none of them phase 3. Ischemic Stroke · Insel Gruppe AG, University Hospital Bern.

Planned enrollment
Largest of 11
2,800 · median 370
Started
2024
with 2 others
Observational
11 of 16
5 open now
Registered
13th of 16
by date

Among the 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern, this one has the largest planned enrollment of the 11 observational ones that give a count, is one of 3 that started in 2024, is one of 11 observational ones, and was the 13th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

7 of the 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Ischemic Stroke by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

DO-IT is an international, prospective observational registry evaluating whether the administration of intravenous thrombolysis (IVT) is safe and improves functional outcome in ischemic stroke patients with recent direct oral anticoagulant (DOAC) intake. For this purpose, information on 2800 adult participants experiencing an acute ischemic stroke will be obtained at several high-volume international stroke centers and divided into three groups: IVT with recent DOACs intake (DOAC+IVT), and recent DOAC intake not receiving IVT (DOAC) as well as anonymized patients without DOAC receiving IVT. The patients are followed up for 90 days after the index event. treatment recommendations from the described observations. The investigators hypothesize that also more liberal decisions for IVT in patients with recent DOAC intake are not associated with an increased risk for symptomatic intracerebral hemorrhage (sICH) and result in better functional outcome at 3 month.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • DOAC (Direct Oral AntiCoagulants)
  • NOAC (Novel Oral AntiCoagulants)
  • Anticoagulation
  • r-tPA (tissue-type plasminogen activator)
  • Alteplase
  • Tenecteplase
  • Rivaroxaban
  • Apixaban
  • Dabigatran
  • Edoxaban
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The in- and exclusion criteria emulate a target trial, thus the investigators want to study a population that is - except from recent DOAC ingestion - eligible for IVT as per standard of care.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of acute ischemic stroke with indication for IVT according to applicable guidelines
  2. Time from symptom onset or last known well \<12 hours
  3. Admission NIHSS of 2 points or more
  4. either DOAC ingestion within 48 hours prior to expected timepoint of IVT bolus, or patient with an ongoing prescription of DOAC, but exact timepoint of last intake not verifiable in the emergency setting. (regardless of whether intravenous thrombolysis was given) OR DOAC prescription (any intake within the last 7 days) and receiving intravenous thrombolysis
  5. (if obtainable and in those international sites where this is legally required) for the prospective part

Exclusion criteria

Exclusion Criteria:

  1. Patient refused the use of biological data for research purposes (Switzerland)
  2. Any acute or subacute intracranial hemorrhage (ICH) identified by admission CT or MRI on brain scan
  3. Documentation of any other absolute to IVT in the medical record
  4. Significant pre-stroke disability (mRS score of 5), including known advanced dementia
  5. Known (serious) sensitivity to Alteplase/Tenecteplase or any of the
  6. Pregnancy or lactating women.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,800 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • DOAC+IVT

    Acute ischemic Stroke patients with recent DOACs intake receive IVT.

    Drug: Tenecteplase and Alteplase

  • DOAC

    Acute ischemic Stroke patients with recent DOAC intake do not receive IVT.

  • IVT Controls

    Acute ischemic Stroke patients without recent DOAC intake receive IVT.

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with symptomatic intracerebral hemorrhage (sICH)

    Defined as worsening of at least 4 points on the National Institutes of Health Stroke Scale and attributed to radiologically evident intracranial hemorrhage.

    Time frame: Within 36 hours after IVT

  2. Dichotomized good functional outcome (mRS 0-2)

    Modified Rankin Scale from 0 (no disability) to 6 (death)

    Time frame: At day 90 or return to baseline (+/- 2 weeks) after admission

Secondary outcomes

  1. Rate of IVT among IVT-eligible DOAC patients

    To determine the rate of IVT in eligible patients with acute ischemic stroke and recent DOAC intake.

    Time frame: Through study completion, an average of 2 years

  2. All-cause mortality, major bleeding and orolingual edema

    Time frame: From date of randomization until the date of all-cause mortality, major bleeding or orolingual edema, whichever came first, assessed up to 7 days.

  3. Categorical shift in the modified Rankin Scale (mRS)

    Modified Rankin Scale from 0 (no disability) to 6 (death)

    Time frame: At Day 90 (+/-2 weeks) after admission

  4. Stroke severity (NIHSS)

    National Institutes of Health Stroke Scale from 0 (no symptoms) to 39 (most severe symptoms)

    Time frame: At 24 hours ±8 hours

  5. Ischemic stroke volume at 24 hours (mL)

    Time frame: At 24 hours ±8 hours

07

Study locations

18 of 33 sites recruiting
  • Medical University of Innsbruck
    Innsbruck, Austria
    Not yet recruiting
    • Christian Böhme, MD, PhD · Principal investigator
  • Cliniques Universitaires Saint Luc
    Brussel, Belgium
    Not yet recruiting
    • Pasquale Scoppettuolo, MD · Contact
    • Pasquale Scoppettuolo, MD · Principal investigator
  • UZ Leuven
    Leuven, 3000, Belgium
    Not yet recruiting
    • Robin Lemmens, Prof · Principal investigator
  • The University of British Columbia | Vancouver General Hospital
    Vancouver, Canada
    Not yet recruiting
    • Thalia Field · Contact
  • CHU Caen
    Caen, France
    Not yet recruiting
    • Marion Boulanger, MD · Principal investigator
  • Nordwest-Krankenhaus Sanderbusch
    Sanderbusch, Germany
    Not yet recruiting
    • Pawel Kermer · Contact
    • Pawel Kermer, MD · Principal investigator
  • Universitäsklinikum Tübingen
    Tübingen, Germany
    Not yet recruiting
    • Julia Zeller · Contact
    • Sven Poli, MD · Principal investigator
  • Dept. of Medicine, University of Thessaly
    Larissa, Thessaly 41110, Greece
    Recruiting
    • George Ntaios, MD, PhD · Principal investigator
    • Dimitra Papadimitriou, MD · Sub investigator
  • A.O.R.N. Antonio Cardarelli Hospital
    Naples, Italy
    Not yet recruiting
    • Paolo Candelaresi, MD · Contact
    • Paolo Candelaresi, MD · Principal investigator
  • Ospedali Riuniti Hospital
    Palermo, Italy
    Not yet recruiting
    • Marina Mannino, MD · Contact
    • Marina Mannino, MD · Principal investigator
  • Ospedale "Bufalini", Cesena
    Perugia, Italy
    Recruiting
  • AUSL-IRCCS di Reggio Emilia
    Reggio Emilia, Italy
    Not yet recruiting
    • Marialuisa Zedde, MD · Contact
    • Marialuisa Zedde · Principal investigator
  • Akershus Hospital
    Oslo, Norway
    Not yet recruiting
    • Espen Kristoffersen, MD · Contact
  • Hospital de Egas Moniz
    Lisboa, Portugal
    Not yet recruiting
  • Clinical Centre of Serbia, University Hospital Belgrade
    Belgrade, Serbia
    Recruiting
    • Visnja Padjen, MD · Contact
    • Visnja Padjen, MD · Principal investigator
  • National University Hospital
    Singapore, 119228, Singapore
    Recruiting
    • Benjamin Tan, MD · Contact
    • Mayank Dalakoti, MD · Principal investigator
    • Benjamin Tan, MD · Principal investigator
  • Ljubljana University Medical Centre
    Ljubljana, Slovenia
    Recruiting
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
    Recruiting
    • Marina Guasch-Jiménez, MD · Contact
    • Marina Guasch-Jiménez, MD · Principal investigator
  • Hospital Universitari de Bellvitge
    Barcelona, Spain
    Not yet recruiting
    • Pere Cardona, MD · Contact
    • Pere Cardona, MD · Principal investigator
  • Kantonsspital Aarau
    Aarau, Switzerland
    Recruiting
    • Timo Kahles · Contact
  • Unispital Basel
    Basel, Switzerland
    Recruiting
    • Gerrit Grosse · Contact
  • Inselspital Bern, University Hospital Bern
    Bern, Switzerland
    Recruiting
    • Freschta Zipser-Mohammadzada · Contact
  • HFR Fribourg
    Fribourg, Switzerland
    Recruiting
    • Friedrich Medlin · Contact
  • University Hospital Geneva
    Geneva, Switzerland
    Recruiting
    • Emmanuel Carrera · Contact
  • CHUV Lausanne
    Lausanne, Switzerland
    Recruiting
    • Patrik Michel · Contact
  • Kantonsspital Lucerne
    Lucerne, Switzerland
    Recruiting
    • Manuel Bolognese · Contact
  • EOC Lugano
    Lugano, Switzerland
    Recruiting
    • Carlo Cereda · Contact
  • Hôpital Neuchâtelois
    Neuchâtel, Switzerland
    Recruiting
    • Susanne Renaud · Contact
  • Kantonsspital St. Gallen
    St. Gallen, Switzerland
    Recruiting
    • Gian Marco De Marchis · Contact
  • Hirslanden Zurich
    Zurich, Switzerland
    Recruiting
    • Nils Peters · Contact
  • University Hospital Zurich
    Zurich, Switzerland
    Recruiting
    • Laura Westphal · Contact
  • Imperial College London NHS Trust
    London, United Kingdom
    Not yet recruiting
    • Lucio D'Anna, MD · Contact
    • Lucio D'Anna, MD · Principal investigator
  • King'S College Hospital Nhs Foundation Trust
    London, United Kingdom
    Not yet recruiting
    • Con Tibajia · Contact
08

References and documents

Individual participant data

Plan to share: Yes — IPDMA of similar observational cohort studies is planned.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: After publication of primary study results

Access criteria: Ethics clearance, agreement with the DO-IT collaboration about terms of use and authorship

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Mar 2026, 26 months after the start.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's planned 26 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2024
First posted
Aug 16, 2024
StartActual
Jan 1, 2024
Primary completionEst.
Mar 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06556446
Collaborators
Swiss Stroke Trialist Association, Swiss Stroke Registry
Responsible party
Sponsor
First posted
Aug 16, 2024
Start date
Jan 1, 2024
Primary completion
Mar 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Aug 16, 2024

Study contacts

Thomas Meinel, MD, PhD
Contact
thomas.meinel@insel.ch
+41 31 66 4 25 67
Freschta Zipser-Mohammadzada, PhD
Contact
nctu@insel.ch
+41 31 63 2 60 83
Thomas Meinel, MD, PhD
study director · Insel Gruppe AG, University Hospital Bern

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion